SCHEMBL4286354

SCHEMBL4286354

c1ccc(CNc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 1.00
ROCK2 O75116 6/20 0.72
CDK2 P24941 6/20 0.72
HIPK2 Q9H2X6 6/20 0.72
PRKACA P17612 5/20 0.72
PIM1 P11309 5/20 0.72
DAPK3 O43293 5/20 0.72
CDK5 Q00535 5/20 0.72
DYRK1A Q13627 5/20 0.72
GSK3B P49841 4/20 0.72
MAPK13 O15264 4/20 0.72
CDK1 P06493 4/20 0.72
MAPK1 P28482 4/20 0.72
CSNK1D P48730 4/20 0.72
MAPK12 P53778 4/20 0.72
CSNK2A1 P68400 4/20 0.72
ROCK1 Q13464 4/20 0.72
AURKB Q96GD4 4/20 0.72
MAP4K4 O95819 3/20 0.72
IRAK4 Q9NWZ3 3/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293420 0.95 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4289150 0.92 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4297753 0.92 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4289509 0.91 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4300135 0.88 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL3670659 0.88 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4292579 0.88 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL4292699 0.85 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL3666765 0.85 CDC7 (0.81) CDC7ROCK2CDK2HIPK2PRKACA
SCHEMBL3673460 0.84 CDC7 (1.00) CDC7ROCK2CDK2HIPK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.